Humanity has never been closer to eradicating polio. It is also, arguably, never been closer to watching the entire enterprise collapse.
The Global Polio Eradication Initiative (GPEI) now administers more than one billion doses of vaccine to roughly 400 million children every single year. In 2023, the entire planet recorded just 12 confirmed cases of wild poliovirus: six in Pakistan and six in Afghanistan. Nigeria, once the epicenter of the continent’s outbreak, has been free of wild polio since 2016. By any measure, this is a public health triumph on a scale that has few parallels in history.
Yet as a Nature editorial published this week argues, the disappearance of polio from the headlines is itself becoming a dangerous liability. Drawing on modeling from Thompson and colleagues in a 2022 paper in Expert Review of Vaccines, the editors warn that abandoning the eradication campaign now could trigger a resurgence of hundreds of thousands of cases per year. The message must change, they contend: from the decades-long refrain of near-victory to a sobering reality check that failure will unleash a fresh wave of paralysis.
The timing of this warning is not accidental. The numbers tell a worrying story. Through July 21 of this year, 18 wild-type polio cases have been confirmed in Pakistan and Afghanistan. That is already more than the total for all of 2023. And the curve is not flattening toward zero the way eradication timelines demand. It is bumping along the bottom, refusing to disappear.
This is the paradox at the heart of modern polio eradication. The closer the campaign gets to zero, the harder it becomes to sustain the funding and operations needed to actually get there. A disease that is nearly invisible is, by definition, easy to deprioritize. The most successful public health campaigns are, in a cruel irony, the ones that make their own continued funding seem unnecessary to policymakers who have never seen a child in an iron lung.
The funding picture has shifted dramatically in 2026, and almost entirely in the wrong direction.
In January, the United States formalized its withdrawal from the World Health Organization, ending the country’s longstanding contributions to multilateral health efforts including polio. The United States Agency for International Development, a critical source of polio surveillance funding, was largely dismantled the previous year, disrupting approximately $85 million in dedicated surveillance support. Some of that money has since been restored through the State Department, but it now flows through bilateral arrangements with 34 individual countries rather than through GPEI’s coordinated multilateral structure. That shift to bilateralism, the editorial suggests, threatens the very architecture that made the eradication campaign viable in the first place.
The results are stark. GPEI faces a 30 percent budget cut in 2026, a reduction that is widely expected to extend into 2027. For an operation that depends on the ability to mount simultaneous vaccination campaigns across multiple countries, border regions, and conflict zones, a 30 percent hole is not an inconvenience; it is an invitation for the virus to reestablish itself.
Not all funders have retreated. The Bill and Melinda Gates Foundation has pledged $1.2 billion for polio eradication covering 2026 through 2029. Saudi Arabia has committed $500 million. The government of Pakistan has allocated $154 million. Rotary International continues to contribute roughly $50 million annually, as it has for decades. And the United States Centers for Disease Control and Prevention has protected approximately $180 million per year in polio-specific activities, even as other parts of the global health apparatus have been dismantled.
But these contributions, substantial as they are, do not fully compensate for the loss of the broad multilateral framework that GPEI relied on. The budget gap forces hard choices: which vaccination campaigns to run, which children to reach first, and which surveillance networks to maintain.
The operational challenges on the ground have never been trivial. More than $3 billion has been spent on eradication efforts in Afghanistan and Pakistan alone over the past decade. Vaccinators in both countries face genuine insecurity, with attacks on health workers a recurring and unresolved threat. Vaccine refusal and skepticism, amplified in some communities by misinformation and in others by genuine distrust of outsiders, remains a persistent obstacle. And the COVID-19 pandemic, while no longer a global emergency, left a legacy of disrupted vaccination schedules that countries are still working to catch up on.
Then there is the problem of vaccine-derived polio. The oral polio vaccine, which contains a weakened live virus, is cheap, easy to administer, and has been the workhorse of the eradication campaign. But in communities where immunization coverage is too low to stop transmission, the weakened virus in the vaccine can circulate, mutate, and regain the ability to cause paralysis. Nigeria, which eliminated wild polio in 2016, has experienced repeated outbreaks of vaccine-derived polio precisely because immunization gaps remain in parts of the country. This is not a failure of the vaccine. It is a failure of coverage. And it means that even as the world chases the last remaining wild-type cases, it must also contend with a secondary epidemic that is the direct result of incomplete vaccination.
The editorial makes a case that the global health community has been telling the wrong story. For years, the narrative has been one of imminent triumph. We are on the verge of only the second disease ever eradicated from the planet, after smallpox. That narrative has motivated donors, mobilized volunteers, and sustained a campaign that has lasted more than three decades. But it also creates a trap. When victory keeps not quite arriving, when the last handful of cases stubbornly refuses to disappear, the story begins to feel like a false promise. Fatigue sets in. Donors wonder whether the money is actually going anywhere. Governments question whether the final push is worth the cost.
The alternative framing, which the Nature editors advocate, is more uncomfortable but perhaps more honest. The goal is not just to eradicate polio. It is to prevent the catastrophe that will follow if the effort is abandoned. Disease modelers who have run the scenarios are clear: without sustained vaccination and surveillance, polio could bounce back with devastating speed, infecting hundreds of thousands of children annually within a few years. The virus has not gone away. It is merely contained, held at bay by a fragile and increasingly underfunded network of vaccinators, surveillance officers, and laboratory technicians working across some of the most difficult terrain on earth.
This argument reframes the entire enterprise. Eradication is not a luxury goal that the world can afford to kick down the road. It is, in the editorial’s view, the only way to avoid an enormously expensive and morally catastrophic failure. The choice is not between spending money on eradication and saving it for something else. The choice is between spending a relatively modest amount to finish the job and spending vastly more to deal with the consequences of not finishing it.
The US withdrawal from the WHO and the shift toward bilateral aid arrangements reflect a deeper erosion of the multilateral institutions that made global health campaigns possible. When the largest economy channels its health funding through bilateral deals with 34 countries rather than through a coordinated international body, vaccination schedules fall out of sync and surveillance data stops flowing as seamlessly. The virus exploits the seams.
The editorial’s central insight is that the polio campaign has reached a point where the language of hope is no longer sufficient. Hope does not fill budget gaps. Hope does not protect vaccinators from attack. Hope does not persuade a skeptical parent to let a stranger put drops in their child’s mouth. What is needed, instead, is a clear-eyed reckoning with the consequences of failure.
The message is not that the finish line is in sight. It is that turning back now would be far more costly than pressing forward. The risk is not that the world will fail to cross the last mile. It is that the world will decide, implicitly or explicitly, that the mile is not worth walking at all.
That would be a mistake the consequences of which would be measured not in dollars or in headlines but in paralyzed children. The disease is still out there. It is waiting. And if the eradication campaign falters, polio will not hesitate to come roaring back.
Reference: Nature Editorial, 655, 1103 (2026), DOI: 10.1038/d41586-026-02308-8